X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
male (59) 59
oncology (58) 58
index medicus (55) 55
middle aged (49) 49
aged (48) 48
cancer (35) 35
adult (31) 31
chemotherapy (31) 31
female (30) 30
aged, 80 and over (27) 27
urology & nephrology (26) 26
prostate cancer (24) 24
treatment outcome (24) 24
care and treatment (23) 23
metastasis (22) 22
survival (22) 22
antineoplastic agents - therapeutic use (20) 20
hematology, oncology and palliative medicine (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
prognosis (17) 17
urology (16) 16
carcinoma (14) 14
neoplasm metastasis (14) 14
docetaxel (13) 13
patient outcomes (13) 13
prostatic neoplasms - pathology (13) 13
article (12) 12
clinical trials as topic (11) 11
prostatic neoplasms - drug therapy (11) 11
clinical trials (10) 10
quality of life (10) 10
survival analysis (10) 10
bone neoplasms - secondary (9) 9
carcinoma, transitional cell - drug therapy (9) 9
disease-free survival (9) 9
double-blind method (9) 9
drug therapy (9) 9
phase-ii trial (9) 9
therapy (9) 9
united states (9) 9
urologic neoplasms - drug therapy (9) 9
analysis (8) 8
carcinoma, renal cell - drug therapy (8) 8
double-blind (8) 8
health aspects (8) 8
immunotherapy (8) 8
kaplan-meier estimate (8) 8
kidney neoplasms - drug therapy (8) 8
paclitaxel (8) 8
research (8) 8
survival rate (8) 8
antineoplastic agents (7) 7
antineoplastic agents - adverse effects (7) 7
cancer therapies (7) 7
carcinoma, renal cell (7) 7
cisplatin (7) 7
clinical-trials (7) 7
diagnosis (7) 7
dosage and administration (7) 7
expression (7) 7
gemcitabine (7) 7
kidney neoplasms - pathology (7) 7
neoplasms - therapy (7) 7
product development (7) 7
prostatic neoplasms - mortality (7) 7
prostatic neoplasms, castration-resistant - drug therapy (7) 7
sunitinib (7) 7
time factors (7) 7
transitional-cell carcinoma (7) 7
urothelial carcinoma (7) 7
abridged index medicus (6) 6
antimitotic agents (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
combined modality therapy (6) 6
drug administration schedule (6) 6
interferon-alpha (6) 6
medical colleges (6) 6
neoplasms - drug therapy (6) 6
patients (6) 6
pazopanib (6) 6
pharmacology & pharmacy (6) 6
practice guidelines as topic (6) 6
prostate (6) 6
protein kinase inhibitors - therapeutic use (6) 6
retrospective studies (6) 6
studies (6) 6
urologic neoplasms - pathology (6) 6
abiraterone acetate (5) 5
adolescent (5) 5
cisplatin - therapeutic use (5) 5
complications and side effects (5) 5
disease progression (5) 5
everolimus (5) 5
lung-cancer (5) 5
medicine & public health (5) 5
medicine, research & experimental (5) 5
metastases (5) 5
mitoxantrone (5) 5
mitoxantrone plus prednisone (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 417 - 425
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 893 - 900
Journal Article
Urology, ISSN 0090-4295, 2017, Volume 104, pp. 150 - 159
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10122, pp. 748 - 757
Journal Article
Cancer, ISSN 0008-543X, 10/1982, Volume 50, Issue 8, p. 1591
The influence of local tumor spread (T-classification) and of tumor size on the occurrence of metastases was studied in 241 patients with testicular germ-cell... 
Dysgerminoma - pathology | Neoplasm Metastasis | Teratoma - pathology | Mesonephroma - pathology | Humans | Middle Aged | Adolescent | Adult | Male | Aged | Neoplasm Staging | Testicular Neoplasms - pathology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 738 - 746
Journal Article